{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:12:45Z","timestamp":1790809965280,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"am","delay-in-days":277,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ctrv.2022.102441","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T20:25:43Z","timestamp":1658867143000},"page":"102441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis"],"prefix":"10.1016","volume":"110","author":[{"given":"Giuseppe","family":"Fallara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Robesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Nocera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Belladelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Malavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-7154","authenticated-orcid":false,"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102441_b0005","unstructured":"US Cancer Society. Prostate at a glance. Estimated new cases, 2021. Accessed April 2022. n.d. https:\/\/cancerstatisticscenter.cancer.org\/#!\/cancer-site\/Prostate."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102441_b0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41391-018-0078-1","article-title":"Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies","volume":"22","author":"Alpajaro","year":"2019","journal-title":"Prostate Can Prostatic Dis"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102441_b0015","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.eururo.2015.02.042","article-title":"Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European randomized study of screening for prostate cancer","volume":"68","author":"Buzzoni","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102441_b0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/pcan.2016.30","article-title":"Increasing incidence of metastatic prostate cancer in the United States (2004\u20132013)","volume":"19","author":"Weiner","year":"2016","journal-title":"Prostate Can Prostat Dis"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102441_b0025","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Longo","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102441_b0030","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.eururo.2013.07.022","article-title":"Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer","volume":"65","author":"Fitzpatrick","year":"2014","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102441_b0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"10024","key":"10.1016\/j.ctrv.2022.102441_b0040","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102441_b0045","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102441_b0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21615-4","article-title":"Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102441_b0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102441_b0060","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102441_b0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102441_b0070","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.ctrv.2022.102441_b0075","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102441_b0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102441_b0085","first-page":"2294","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized","volume":"39","author":"Chi","year":"2022","journal-title":"Double-Blind, Phase III TITAN Study abstract"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102441_b0090","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102441_b0095","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, Mcdermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration- sensitive prostate cancer (PEACE-1): a multicentre , open- label , randomised , phase 3 study with a 2 \u00d7 2 factorial design n.d.:1\u201313."},{"key":"10.1016\/j.ctrv.2022.102441_b0100","doi-asserted-by":"crossref","unstructured":"Agarwal N, Mundle S, Dearden L, Potluri RC, Nair S, Mehra M. Use and outcomes in men with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel in addition to androgen deprivation therapy (ADT): Analysis of real-world data in the United States (US). J Clin Oncol 2020;38:e19322\u2013e19322. doi:10.1200\/JCO.2020.38.15_suppl.e19322.","DOI":"10.1200\/JCO.2020.38.15_suppl.e19322"},{"key":"10.1016\/j.ctrv.2022.102441_b0105","doi-asserted-by":"crossref","unstructured":"Ke X, Lafeuille M-H, Romdhani H, Kinkead F, Francis PSJ, D\u2019Andrea D, et al. Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US). J Clin Oncol 2020;38:e19131\u2013e19131. doi:10.1200\/JCO.2020.38.15_suppl.e19131.","DOI":"10.1200\/JCO.2020.38.15_suppl.e19131"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102441_b0110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/0284186X.2021.2023215","article-title":"Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study","volume":"61","author":"Gedeborg","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2022.102441_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.euros.2020.12.006","article-title":"Effectiveness of docetaxel for metastatic hormone-sensitive prostate cancer in clinical practice","volume":"24","author":"Lendorf","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ctrv.2022.102441_b0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.euros.2021.08.008","article-title":"Docetaxel treatment for metastatic hormone-sensitive prostate cancer in daily practice","volume":"33","author":"de Groot","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102441_b0125","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.119.313046","article-title":"Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses","volume":"40","author":"Hu","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ctrv.2022.102441_b0130","unstructured":"AUA Guidelines 2022 Prostate Cancer n.d."},{"key":"10.1016\/j.ctrv.2022.102441_b0135","unstructured":"EAU Guidelines Prostate Cancer. Edn. presented at the EAU Annual Congress Amsterdam 2022. n.d."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102441_b0140","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines Insights: Prostate Cancer, Version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102441_b0145","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102441_b0150","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102441_b0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0163278702025001006","article-title":"To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data","volume":"25","author":"Stewart","year":"2002","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.ctrv.2022.102441_b0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cct.2017.02.007","article-title":"Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale","volume":"63","author":"Satagopan","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ctrv.2022.102441_b0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ctrv.2022.102441_b0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2753.2010.01516.x","article-title":"Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research","volume":"18","author":"Armijo-Olivo","year":"2012","journal-title":"J Eval Clin Pract"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102441_b0175","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J"},{"key":"10.1016\/j.ctrv.2022.102441_b0180","doi-asserted-by":"crossref","first-page":"102360","DOI":"10.1016\/j.ctrv.2022.102360","article-title":"Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis","volume":"104","author":"Martini","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102441_b0185","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.eururo.2019.05.037","article-title":"Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis","volume":"76","author":"Niglio","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2022.102441_b0190","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102441_b0195","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2021.04.003","article-title":"Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis","volume":"8","author":"Wenzel","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ctrv.2022.102441_b0200","doi-asserted-by":"crossref","unstructured":"Davis ID, Martin AJ, Zielinski RR, Thomson A, Tan TH, Sandhu S, et al. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 2022;40:LBA5004\u2013LBA5004. doi:10.1200\/JCO.2022.40.17_suppl.LBA5004.","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA5004"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102441_b0205","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41391-020-0231-5","article-title":"Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial","volume":"23","author":"Martini","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"24","key":"10.1016\/j.ctrv.2022.102441_b0210","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102441_b0215","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102441_b0220","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy284.006","article-title":"LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednison","author":"Matsubara","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102441_b0225","doi-asserted-by":"crossref","unstructured":"Halabi S, Roy A, Rydzewska L, Godolphin P, Parmar MKB, Hussain MHA, et al. Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 2022;40:5006. doi:10.1200\/JCO.2022.40.16_suppl.5006.","DOI":"10.1200\/JCO.2022.40.16_suppl.5006"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:26:56Z","timestamp":1759656416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":45,"alternative-id":["S0305737222001104"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102441","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102441"}}